DEPO TEST (AMPS) Unigen Life Sciences

$45.00

DEPO TEST (AMPS) Unigen Life Sciences

$45.00

Producer: Unigen Life Sciences
Model: Testosterone Enanthate 5 ampoules of 1ml (250mg/ml)

Free worldwide shipping on all orders over $300

  • 30 days easy returns
  • Order yours before 1.30pm for same day dispatch
Guaranteed Safe Checkout

Description

Pack: 5 ampoules of 1ml (250mg/ml)

Substance: Testosterone Enanthate

Brand: Unigen Life Sciences

DEPO TEST 250 is used in replacement therapy in conditions associated with deficiency of endogenous testosterone. It is an oil based injectable, designed to release testosterone slowly from the injection site. Once administered, serum concentrations of this hormone will rise for several days, and remain markedly elevated for approximately two weeks. For medical purposes this is the most widely prescribed testosterone used regularly to treat cases of hypogonadism and other disorders related to androgen deficiency. As with all testosterone products it has a strong anabolic activity, with a pronounced androgenic component. Significant gains in strength and muscle tissue as well a noticeable increase in libido.

INDICATIONS

Males
Testosterone Enanthate Injection is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.
Primary hypogonadism : Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy.
Hypogonadotropic hypogonadism : Idiopathic gonadotropin or luteinizing hormone – releasing hormone (LHRH) deficiency, or pituitary – hypothalamic injury from tumors, trauma, or radiation.
Delayed Puberty : Testosterone Enanthate Injection may be used to stimulate puberty in carefully selected males with clearly delayed puberty.

Females

Metastatic mammary cancer: Testosterone Enanthate Injection may be used secondarily in women with advancing inoperable metastatic mammary cancer who are one to five years postmenopausal. It has also been used in premenopausal women who have benefited from oophorectomy and are considered to have a hormone-responsive tumor.